Ignite Creation Date:
2024-05-06 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 2:25 PM
Study NCT ID:
NCT05252390
Status:
RECRUITING
Last Update Posted:
2024-05-29
First Post:
2022-01-28
Brief Title:
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Sponsor:
Nuvation Bio Inc
Organization:
Nuvation Bio Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Breast Tumor |
| Advanced Solid Tumor |
| Ovarian Cancer |
| Ovary Cancer |
| Cancer of Ovary |
| Cancer of the Ovary |
| Ovary Neoplasm |
| Pancreatic Cancer |
| Pancreas Cancer |
| Cancer of Pancreas |
| Cancer of the Pancreas |
| Pancreas Neoplasm |
| Prostate Cancer |
| Prostatic Cancer |
| Cancer of Prostate |
| Cancer of the Prostate |
| Prostate Neoplasm |
| Castrate Resistant Prostate Cancer |
| Castration Resistant Prostatic Cancer |
| Castration Resistant Prostatic Neoplasms |
| Triple-negative Breast Cancer |
| Triple Negative Breast Cancer |
| Triple Negative Breast Neoplasms |
| Breast Cancer |
| Breast Carcinoma |
| Cancer of Breast |
| Cancer of the Breast |
Keywords:
| Name | View |
|---|---|
| homologous recombination deficiency | View |
| Phase 2 | View |
| NUV-868 | View |
| olaparib | View |
| enzalutamide | View |
| Xtandi | View |
| ovarian cancer | View |
| pancreatic cancer | View |
| Phase 1 | View |
| metastatic castration-resistant prostate cancer | View |
| triple-negative breast cancer | View |
| Lynparza | View |
| PARP inhibitor | View |
| BET inhibitor | View |
| BRCA mutation | View |
| BRCA1 | View |
| BRCA2 | View |
| HRD | View |
| HRR deficiency | View |